Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bridge Bioresearch (BBR), a drug development company, has received US patent for its CD14 molecule indicated for treatment of diabetes Type 2, obesity, atheroschlerosis as well as inflammatory diseases.
Subscribe to our email newsletter
BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule, the company said.
The glycoprotein CD14 on the surface of human macrophages is important for the recognition and clearance of apoptotic cells.
CD14 can also act as a receptor that binds bacterial LPS, triggering inflammatory responses.Over stimulation of CD14 by LPS can cause the often fatal toxic-shock syndrome.
BBR CEO Soren Stenderup said the granting of the US patent further strengthens the IP position of CD14 as this complements the already issued European patent.